Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 9/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SLC15A1 | P46059 | 2/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
| ▸ | LAP3 | P28838 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12869912 | 0.81 | LTA4H (0.54) | LTA4HALDH1A1IDO1SLC15A1SLC1A3 | |
| SCHEMBL17375358 | 0.81 | LTA4H (0.54) | LTA4HALDH1A1IDO1SLC15A1SLC1A3 | |
| SCHEMBL29500229 | 0.81 | ALDH1A1 (0.42) | ALDH1A1MAPTHPGDSLC15A1 | |
| SCHEMBL28192478 | 0.80 | LTA4H (0.56) | LTA4HALDH1A1IDO1SLC15A1SLC1A3 | |
| SCHEMBL21232385 | 0.80 | LTA4H (0.56) | LTA4HALDH1A1IDO1SLC15A1SLC1A3 | |
| SCHEMBL124387 | 0.80 | LTA4H (0.56) | LTA4HALDH1A1IDO1SLC15A1SLC1A3 | |
| SCHEMBL561573 | 0.80 | LTA4H (0.56) | LTA4HALDH1A1IDO1SLC15A1SLC1A3 | |
| SCHEMBL21274457 | 0.80 | LTA4H (0.47) | LTA4HALDH1A1IDO1HPGDSLC15A1 | |
| SCHEMBL21274456 | 0.80 | LTA4H (0.47) | LTA4HALDH1A1IDO1HPGDSLC15A1 | |
| SCHEMBL27324538 | 0.80 | LTA4H (0.59) | LTA4HALDH1A1SLC15A1SLC1A3SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-02-02 | — | — | US | disclosed |
| US-8841278-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-8822430-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2014-09-02 | — | — | US | disclosed |
| US-20140039021-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-8575118-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20130137877-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | LTA4H 3111/4885ALDH1A1 3957/4885IDO1 889/4885 |
| US-20130137877-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | LTA4H 3111/4885ALDH1A1 3957/4885IDO1 889/4885 |
| US-20140039021-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | LTA4H 3111/4885ALDH1A1 3957/4885IDO1 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.